Since when is news from FDA hype??? Give me an answer. Bought more.
K results, new cohort
Combo K trial starting in Italy.
Maybe a partner.
Depending on Stock price Uplisting late 4 qtr.
Mako Research goes long
It's not a issue. CTIX is wanting results from trials before a partnership. Otherwise you get r*ped. Then $$$ will not be an issue.
I would add that they are seeing durations at 11 months now, where a month or two is the norm for very advanced tumors. Stock should be double here.
is behind it. Seeking compensation for shareholder losses.
Non-Inferiority gets approval. CEMP is dirt cheap either with non-superiority or with Superiority. What's the problem...there isn't one. Just keep adding at these ridiculous prices.
be different. Maybe the data isn't looking to good for Celg to pay up. IMHO
REGN will need to decide if its even worth marketing, developing and taking to market. Better drugs are out there even better coming. I don't think its worth it. IMHO.
The recent partnerships and buyouts have potential acquirer's a little on edge. If you were interested in CEMP, you may not want to wait for all the data to be presented to the world; otherwise, you may lose out. So it wouldn't surprise me if a very good offer was made.
COPD data to be presented later this year, a major catalyst I like the way they plan to add indications as studies complete to the NDA they are currently working on.